CSL Limited (CMXHF) Q2 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, good morning and welcome to CSL's first half results call for fiscal 2024. It's Mark Dearing speaking and I'm pleased to be joined by several of CSL's leadership team. With me here are Dr Paul McKenzie, CSL's Chief Executive Officer, Joy Linton, CSL's Chief Financial Officer. Dr. Bill Mezzanotti, Executive VP and Head of Research and Development. Andy Schmelz, Executive VP, CSL Bearing. Stephen Marlow, Senior VP and General Manager, CSL Securus. Hervé Gissereau, Senior VP and General Manager, CSL V4. Today, we're going to vary a little bit from past practice. Paul will, of course, provide an overview of the results and operation. Then we'll have Bill Mezzanotti providing some updates on the R&D portfolio, including the CSL 112 top-line data announced yesterday. Joy will then provide some additional detail on the financials, and Paul will finish up with some comments on Outlook, after which we'll move to Q&A. And as usual, with a view to giving everybody an opportunity to ask a question, could you please limit your questions to two? If you do have a further question, you are of course welcome to rejoin the queue. Please note, this briefing is being webcast. And lastly, before we start, I draw your attention to the forward statement disclaimer contained in the slide deck. And with that, I'll pass over to Paul McKenzie. Paul. Thank you, Mark, and good morning, everyone. Great to be back in Melbourne. Thank you for joining today's CSL half-year result call for 2024. As Mark mentioned, we released top-line data for CSL 112 yesterday, and Dr. Bill Mezzanotti will talk to this shortly. While not the clinical outcome we were looking for, the study was well designed and well executed. I would like to second Bill's thanks and gratitude to the entire CSL 1...